These percentages are notably lower than those reported for CagriSema, though cross-trial comparisons are imperfect
8.4 Pediatric Use Safety and effectiveness of SOLIQUA 100/33 have not been established in pediatric patients
unfortunately, it didnt stick around
Expanding Indications Research is exploring GLP-1 molecules for conditions beyond diabetes and obesity, further expanding future demand
This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers
However, there are alternative medications to treat diabetes, such as insulin, Metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose co-transporter 2 (SGLT2) inhibitors, meglitinides, thiazolidinediones and alpha-glucosidase inhibitors